A retrospective analysis (n = 15,100) involving IBD patients was undertaken to assess the impact of biologic therapies (all of which were TNF-α agents), corticosteroids, and their combination on the risk of VTE over 12 months of follow-up. This evidence concerns the gene TNF and inflammatory bowel disease.